Literature DB >> 32671407

Long-term Outcome of Short-course High-dose Glucocorticoids for Severe Acute Respiratory Syndrome (SARS): A 17-Year Follow-up in SARS Survivors.

Chor-Wing Sing1, Kathryn C B Tan2, Ian C K Wong1,3, Bernard M Y Cheung2, Ching-Lung Cheung1.   

Abstract

Use of high-dose glucocorticoids for COVID-19 (caused by SARS-CoV-2) is controversial because of safety concerns. We examined the long-term consequences of glucocorticoid use in severe acute respiratory syndrome (caused by SARS-CoV-1) survivors. Results showed that high-dose glucocorticoids greatly increased the long-term risk of avascular necrosis but not other major diseases.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SARS; avascular necrosis; clinical outcomes; follow-up; glucocorticoids

Mesh:

Substances:

Year:  2021        PMID: 32671407      PMCID: PMC7454482          DOI: 10.1093/cid/ciaa992

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  2 in total

1.  Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.

Authors:  Yingying Lu; Feng Liu; Gangling Tong; Feng Qiu; Pinhong Song; Xiaolin Wang; Xiafei Zou; Deyun Wan; Miao Cui; Yunsheng Xu; Zhihua Zheng; Peng Hong
Journal:  Signal Transduct Target Ther       Date:  2021-03-03

Review 2.  Managing SARS-CoV2 Infections Through Resolution of Inflammation by Eicosanoids: A Review.

Authors:  Ameena Mohammed; Arunasree M Kalle; Pallu Reddanna
Journal:  J Inflamm Res       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.